Clinical Trials | March 09, 2026
DiaMedica bags Health Canada nod for Phase 2 preeclampsia trial
DiaMedica said it plans to launch the trial later in 2026
DiaMedica said it plans to launch the trial later in 2026
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
40+ most innovative startups with disruptive contributions across MedTech, Medical Devices, BioPharma, Cell and Gene Therapy, AI and ML, Nutraceuticals, and Biomarkers exhibited their cutting-edge solutions
Alto met its enrollment goal with 83 patients across 13 US clinical sites
The paper highlights how conditions common across India—including anemia, inherited hemoglobin disorders, and glucose-6-phosphate dehydrogenase (G6PD) deficiency—can significantly distort HbA1c readings
The findings, based on an exploratory analysis, indicate that CD47 expression may predict which patients benefit most from the therapy
N17350 is the company’s first-in-class tumor-directed therapeutic, designed to harness the ELANE pathway
Subscribe To Our Newsletter & Stay Updated
